192 related articles for article (PubMed ID: 34779127)
1. Metformin induces insulin secretion by preserving pancreatic aquaporin 7 expression in type 2 diabetes mellitus.
Kimura T; Kaneto H
J Diabetes Investig; 2022 Feb; 13(2):227-229. PubMed ID: 34779127
[TBL] [Abstract][Full Text] [Related]
2. Metformin inhibits MAPK signaling and rescues pancreatic aquaporin 7 expression to induce insulin secretion in type 2 diabetes mellitus.
He X; Gao F; Hou J; Li T; Tan J; Wang C; Liu X; Wang M; Liu H; Chen Y; Yu Z; Yang M
J Biol Chem; 2021 Aug; 297(2):101002. PubMed ID: 34303707
[TBL] [Abstract][Full Text] [Related]
3. Metformin Preserves β-Cell Compensation in Insulin Secretion and Mass Expansion in Prediabetic Nile Rats.
Huang H; Lorenz BR; Zelmanovitz PH; Chan CB
Int J Mol Sci; 2021 Jan; 22(1):. PubMed ID: 33401592
[TBL] [Abstract][Full Text] [Related]
4. Role of AMPK in pancreatic beta cell function.
Fu A; Eberhard CE; Screaton RA
Mol Cell Endocrinol; 2013 Feb; 366(2):127-34. PubMed ID: 22766107
[TBL] [Abstract][Full Text] [Related]
5. Preserving Insulin Secretion in Diabetes by Inhibiting VDAC1 Overexpression and Surface Translocation in β Cells.
Zhang E; Mohammed Al-Amily I; Mohammed S; Luan C; Asplund O; Ahmed M; Ye Y; Ben-Hail D; Soni A; Vishnu N; Bompada P; De Marinis Y; Groop L; Shoshan-Barmatz V; Renström E; Wollheim CB; Salehi A
Cell Metab; 2019 Jan; 29(1):64-77.e6. PubMed ID: 30293774
[TBL] [Abstract][Full Text] [Related]
6. Vildagliptin added to metformin on β-cell function after a euglycemic hyperinsulinemic and hyperglycemic clamp in type 2 diabetes patients.
Derosa G; Ragonesi PD; Carbone A; Fogari E; Bianchi L; Bonaventura A; Romano D; Cicero AF; Maffioli P
Diabetes Technol Ther; 2012 Jun; 14(6):475-84. PubMed ID: 22512264
[TBL] [Abstract][Full Text] [Related]
7. Comparisons between dipeptidyl peptidase-4 inhibitors and other classes of hypoglycemic drugs using two distinct biomarkers of pancreatic beta-cell function: A meta-analysis.
Takahashi M; Shibasaki M; Echizen H; Kushiyama A
PLoS One; 2020; 15(7):e0236603. PubMed ID: 32706828
[TBL] [Abstract][Full Text] [Related]
8. Identification of the signals for glucose-induced insulin secretion in INS1 (832/13) β-cells using metformin-induced metabolic deceleration as a model.
Lamontagne J; Al-Mass A; Nolan CJ; Corkey BE; Madiraju SRM; Joly E; Prentki M
J Biol Chem; 2017 Nov; 292(47):19458-19468. PubMed ID: 28972173
[TBL] [Abstract][Full Text] [Related]
9. Metformin and insulin meet in a most atypical way.
White MF
Cell Metab; 2009 Jun; 9(6):485-7. PubMed ID: 19490902
[TBL] [Abstract][Full Text] [Related]
10. An overview of pancreatic beta-cell defects in human type 2 diabetes: implications for treatment.
Marchetti P; Dotta F; Lauro D; Purrello F
Regul Pept; 2008 Feb; 146(1-3):4-11. PubMed ID: 17889380
[TBL] [Abstract][Full Text] [Related]
11. Hypoglycaemic and anti-hyperglycaemic drugs for the control of diabetes.
Bailey CJ
Proc Nutr Soc; 1991 Dec; 50(3):619-30. PubMed ID: 1809970
[No Abstract] [Full Text] [Related]
12. Eight weeks of treatment with long-acting GLP-1 analog taspoglutide improves postprandial insulin secretion and sensitivity in metformin-treated patients with type 2 diabetes.
Gastaldelli A; Nauck MA; Balena R
Metabolism; 2013 Sep; 62(9):1330-9. PubMed ID: 23831441
[TBL] [Abstract][Full Text] [Related]
13. Metformin Perturbs Pancreatic Differentiation From Human Embryonic Stem Cells.
Nguyen L; Lim LY; Ding SSL; Amirruddin NS; Hoon S; Chan SY; Teo AKK
Diabetes; 2021 Aug; 70(8):1689-1702. PubMed ID: 33958328
[TBL] [Abstract][Full Text] [Related]
14. Goals of treatment for type 2 diabetes: beta-cell preservation for glycemic control.
Marchetti P; Lupi R; Del Guerra S; Bugliani M; D'Aleo V; Occhipinti M; Boggi U; Marselli L; Masini M
Diabetes Care; 2009 Nov; 32 Suppl 2(Suppl 2):S178-83. PubMed ID: 19875548
[No Abstract] [Full Text] [Related]
15. Effect of anti-IL-1β antibody (canakinumab) on insulin secretion rates in impaired glucose tolerance or type 2 diabetes: results of a randomized, placebo-controlled trial.
Rissanen A; Howard CP; Botha J; Thuren T;
Diabetes Obes Metab; 2012 Dec; 14(12):1088-96. PubMed ID: 22726220
[TBL] [Abstract][Full Text] [Related]
16. Restoring post-prandial insulin release in type 2 diabetes.
Andrews J
Hosp Med; 2002 Feb; 63(2):95-8. PubMed ID: 11902096
[TBL] [Abstract][Full Text] [Related]
17. Metformin: fifty-two not out.
Campbell IW
J Indian Med Assoc; 2009 Nov; 107(11):779-84. PubMed ID: 20469782
[No Abstract] [Full Text] [Related]
18. Prevention by metformin of alterations induced by chronic exposure to high glucose in human islet beta cells is associated with preserved ATP/ADP ratio.
Masini M; Anello M; Bugliani M; Marselli L; Filipponi F; Boggi U; Purrello F; Occhipinti M; Martino L; Marchetti P; De Tata V
Diabetes Res Clin Pract; 2014 Apr; 104(1):163-70. PubMed ID: 24462282
[TBL] [Abstract][Full Text] [Related]
19. Metformin, beyond an insulin sensitizer, targeting heart and pancreatic β cells.
Yang X; Xu Z; Zhang C; Cai Z; Zhang J
Biochim Biophys Acta Mol Basis Dis; 2017 Aug; 1863(8):1984-1990. PubMed ID: 27702625
[TBL] [Abstract][Full Text] [Related]
20. Targeting the insulin granule for modulation of insulin exocytosis.
Yau B; Hocking S; Andrikopoulos S; Kebede MA
Biochem Pharmacol; 2021 Dec; 194():114821. PubMed ID: 34748819
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
